Skip to main content
. Author manuscript; available in PMC: 2021 Jul 26.
Published in final edited form as: Med. 2021 Apr 21;2(7):836–850.e10. doi: 10.1016/j.medj.2021.03.017

Figure 2. Clinical utility validation 1: cirrhosis with mixed HCC etiologies (prospective-retrospective cohort).

Figure 2.

(A) Study design. (B) Patten of the PLSec protein abundance and associated clinical variables. (C) Time-dependent AUC of PLSec-AFP score, PLSec alone, and AFP alone. (D) Association of PLSec-AFP with incident HCC. (E) Calibration plot of PLSec-AFP at various time points. The grey dash line indicates ideal calibration. (F) Association of PLSec-AFP with incident HCC in various subgroups.

See also Figure S1 and Table S1–3.

PLSec, prognostic liver secretome signature; HCC, hepatocellular carcinoma; IQR, interquartile range; AFP, alpha-fetoprotein; HCV, hepatitis C virus; HBV, hepatitis B virus; ARLD, alcohol-related liver disease; NAFLD, non-alcoholic fatty liver disease; AUC, area under the receiver operating characteristic curve; HR, hazard ratio; CI, confidence interval.